atai Life Sciences launches TryptageniX to further expand atai’s robust intellectual property portfolio and strengthen atai's supply chain
TryptageniX, a majority-owned joint venture with CB Therapeutics, employs bioprospecting to develop new chemical entities with potential applications in mental health. This new platform company will ...